DocGo Inc.
DocGo provides mobile health, virtual care management and medical transportation services through a technology platform, a network of healthcare professionals and medical response vehicles. Its customers include municipalities, hospitals and health systems, insurers, physician practices, businesses and employers. Mobile Health Services bring evaluations, diagnostics, treatment and preventive care to patients’ homes, workplaces and other locations, and include remote monitoring and health plan care gap programs. Transportation Services, offered under the Ambulnz brand, provide digitally enabled transfers between clinical settings and transportation to clinical services. DocGo earns money by providing these services to healthcare organizations, payors, public-sector customers and other clients. DocGo has three reporting segments: Mobile Health Services, Transportation Services and Corporate. Its services are available in all 50 states and the United Kingdom. As of December 31, 2025, it had 582 vehicles in service in the United States and 288 in the United Kingdom. DocGo is headquartered in New York, New York.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $DCGO in the last 30 days.
See all $DCGO insider activity →DocGo and CEO Lee Bienstock agreed to a transition and separation plan. Bienstock will continue until a new CEO is appointed by March 31, 2027. The agreement includes a $90,000 monthly salary, severance of $785,000, and other benefits. The company is currently searching for a successor.
DocGo Inc. (DCGO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously announced, DocGo Inc. (the “Company”) is conducting a search for a new Chief Executive Officer as the employm
Needham kept its Buy rating on DocGo but reduced its price target from $3 to $1, a 66.7% decrease. The firm's updated target reflects a lower valuation for the company.
Over the past 7 days, AlphAI's AI scored 10 news stories mentioning DCGO (DocGo Inc.). Coverage has skewed bearish: 0 bullish, 4 neutral, and 6 bearish.
Recent DCGO coverage spans corporate actions, earnings and financial news.
The leadership change may create short‑term uncertainty and could pressure the stock until a new CEO is named.
The disclosed severance and transition terms may weigh on the balance sheet and signal leadership uncertainty.
Needham kept its Buy rating on DocGo but reduced its price target from $3 to $1, a 66.7% decrease. The firm's updated target reflects a lower valuation for the company.
Guidance slightly below prior expectations, suggesting modest downside pressure.
Margin expansion and a issued full-year revenue outlook, alongside an announced CEO search, increase uncertainty around near-term execution and profitability trajectory.
AlphAI scores every news story that mentions DCGO with an AI model for sentiment and relevance, and aggregates insider trades from DocGo Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
DocGo and CEO Lee Bienstock agreed to a transition and separation plan. Bienstock will continue until a new CEO is appointed by March 31, 2027. The agreement includes a $90,000 monthly salary, severance of $785,000, and other benefits. The company is currently searching for a successor.
DocGo Inc. (DCGO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously announced, DocGo Inc. (the “Company”) is conducting a search for a new Chief Executive Officer as the employm
Needham kept its Buy rating on DocGo but reduced its price target from $3 to $1, a 66.7% decrease. The firm's updated target reflects a lower valuation for the company.
DocGo Inc (DCGO) reported its first revenue growth since 2023 in Q3 2026, with expectations of continued growth in 2027. The company anticipates positive EBITDA for 2027, driven by revenue gains in medical transportation and mobile health lines. DocGo is also focusing on restructuring and renegotiating contracts to improve profitability. The company is awaiting regulatory approval for the Hycuity Health acquisition, expected to close by the end of November.
DocGo Inc. (DCGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DocGo Announces Third Quarter 2026 Results Gross Margin Improves 280 Basis Points Over Q2 Due to Company Profitability Initiatives Board of Directors Initiates CEO Search as Lee Bienstock's Employment Contract Expires at Year-End; Lee Bienstock to Continue as CEO and
DocGo secured up to $102M in term loans at SOFR+7.5% maturing in 2029, issued 4M warrants at $0.5039, and terminated an undrawn Citibank revolver. The financing aims to boost liquidity and support operations, including potential mergers, according to the company.
DocGo Inc. (DCGO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into a Material Definitive Agreement. Amended and Restated Credit Agreement and Guaranty On October 1, 2026, Hicuity and Ambulnz (together, the "Borrowers"), DocGo, certain subsidiaries of Ambulnz as guarantors, the lenders from time to time party thereto (the "Le
FORT Robotics to go public via SPAC deal valued at $500M, trading as FROB. DocGo acquires Hicuity Health to expand virtual care. Lydonia acquires Incin.ai assets. DocGo reports Q2 2026 growth, expects $305M-$310M revenue for 2026.
DocGo Inc (DCGO) reported Q2 2026 revenue of $73.4M, down from $80.4M YoY, and widened its adjusted EBITDA loss guidance to $17M-$22M. Gross margins declined due to lower margins in the Mobile Health segment and higher fuel costs. The company's cash position decreased to $48.1M. The Hicuity acquisition faces regulatory and customer approval hurdles. Organic revenue grew approximately 5% YoY. The company aims to achieve adjusted EBITDA breakeven by the end of 2026 through revenue growth, improved
DocGo (DCGO) shares fell about 12.7% pre-open to $0.62 after its Q2 2026 results missed expectations. Adjusted loss per share was $0.16 vs $0.10 forecast, revenue was $73.4M vs $75.4M. DocGo cut full-year 2026 adjusted EBITDA guidance to a $17M to $22M loss and agreed to acquire Hicuity Health, largely via debt assumption and new financing.
